Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer
- 16 November 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (3), 759-774
- https://doi.org/10.1158/1078-0432.ccr-20-3396
Abstract
Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive form of castration-resistant prostate cancer (CRPC) for which effective therapies are lacking. We previously identified carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) as a promising NEPC cell surface antigen. Here we investigated the scope of CEACAM5 expression in end-stage prostate cancer, the basis for CEACAM5 enrichment in NEPC, and the therapeutic potential of the CEACAM5 antibody-drug conjugate labetuzumab govitecan in prostate cancer. Experimental Design: The expression of CEACAM5 and other clinically relevant antigens was characterized by multiplex immunofluorescence of a tissue microarray comprising metastatic tumors from 34 lethal mCRPC cases. A genetically defined neuroendocrine transdifferentiation assay of prostate cancer was developed to evaluate mechanisms of CEACAM5 regulation in NEPC. The specificity and efficacy of labetuzumab govitecan was determined in CEACAM5+ prostate cancer cell lines and patient-derived xenografts models. Results: CEACAM5 expression was enriched in NEPC compared to other mCRPC subtypes and minimally overlapped with PSMA, PSCA, and Trop2 expression. We focused on a correlation between the expression of the pioneer transcription factor ASCL1 and CEACAM5 to determine that ASCL1 can drive neuroendocrine reprogramming of prostate cancer which is associated with increased chromatin accessibility of the CEACAM5 core promoter and CEACAM5 expression. Labetuzumab govitecan induced DNA damage in CEACAM5+ prostate cancer cell lines and marked antitumor responses in CEACAM5+ CRPC xenograft models including chemotherapy-resistant NEPC. Conclusions: Our findings provide insights into the scope and regulation of CEACAM5 expression in prostate cancer and strong support for clinical studies of labetuzumab govitecan for NEPC.Keywords
Other Versions
Funding Information
- Department of Defense Prostate Cancer Research Program Awards (W81XWH-17-1-0129)
- Department of Defense Prostate Cancer Research Program Awards (W81XWH-18–1-0347)
- Department of Defense (W81XWH-19-1-0758, W81XWH19-1-0569)
- Department of Defense Prostate Cancer Research Program Early Investigator Research Award (W81XWH-17–1-0380)
- Idea Development Award-Partnering-PI (W81XWH-17-1-0414)
- NIH (PO1 CA163227)
This publication has 60 references indexed in Scilit:
- Carcinoembryonic antigen (CEA)-related cell adhesion molecules are co-expressed in the human lung and their expression can be modulated in bronchial epithelial cells by non-typable Haemophilus influenzae, Moraxella catarrhalis, TLR3, and type I and II interferonsRespiratory Research, 2013
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug TargetsCancer Discovery, 2011
- CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 ImmunoconjugatesClinical Cancer Research, 2009
- Acheate‐scute like 1 (Ascl1) is required for normal delta‐like (Dll) gene expression and notch signaling during retinal developmentDevelopmental Dynamics, 2009
- Irinotecan therapy and molecular targets in colorectal cancer: A systemic reviewWorld Journal of Gastroenterology, 2009
- CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-β signalingOncogene, 2007
- Requirement of the MASH-1 transcription factor for neuroendocrine differentiation of thyroid C cellsJournal of Neurobiology, 1998
- Transcriptional Regulation of the Carcinoembryonic Antigen GeneOnline Journal of Public Health Informatics, 1995
- Metastatic potential of human colorectal carcinoma SW1222 cells transfected with cDNA encoding carcinoembryonic antigenClinical & Experimental Metastasis, 1994
- The Effect of Sodium Butyrate and Retinoic Acid on Growth and CEA Production in a Series of Human Colorectal Tumor Cell Lines Representing Different States of DifferentiationCancer Investigation, 1988